Abstract: Silicic acid modulates (i.e. enhances or inhibits) adenylate cycloase activity. This effect appears to be a general one, inasmuch as the modulation has occurred in all tissues studied. The results suggest that silicic acid can be used in human and veterinary medicine to modulate hormone or neurotransmitter response. The results also indicate that silicic acid can be used to prevent, treat, or delay the onset of calcium-related bone disease, or to improve bone strength in an vertebrate having a bone strength less than desired.

Abstract: This invention provides compositions comprising a compound having the structural formula ##STR1## wherein each X, Y and Z may represent oxygen, sulfur or two hydrogen atoms, provided however that, when Z represents two hydrogen atoms, both X and Y represent oxygen or sulfur and when Z represents oxygen or sulfur at least one of X and Y must represent oxygen or sulfur; m is 2-6; R' is H or a lower alkyl group having 1-4 carbon atoms; n is 0-17 and R is --CH.sub.3, ##STR2## wherein R" is H or halogen. The invention also provides compositions comprising a physiologically-active agent and the hereinabove recited 1-substituted azacycloalkane compound in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal.

Abstract: A method of selectively stimulating D-2 dopamine receptors in humans comprising administering to a human requiring D-2 dopamine receptor stimulation, a therapeutically effective amount of 2-(N-phenylethyl-N-propylamino)-5-hydroxytetralin or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure describes compositions and methods for improved delivery of plant nutrients comprising contacting a plant with a composition comprising an effective amount of a plant nutrient and an effective delivery enhancing amount of compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group having 1-4 carbon atoms, m is 3-7, n is 0-17 and R is --CH.sub.3, ##STR2## where R" is H or halogen, with the proviso that if m is 3 and R is CH.sub.3, then n is 5-17.

Abstract: A method for treating mouth pain by administering to a human having such pain an effective mouth pain reducing amount of dextromethorphan, preferably as the hydrobromide.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: In a method of synthesis of 1-substituted azacycloalkan-2-ones with primary alkyl halides and aralkyl halides as alkylating agents, the improvement comprising carrying out the N-alkylation in the presence of a phase transfer catalyst having the structural formula ##STR1## where X is suitable anion; and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each alkyl or aralkyl groups having 1-18 carbon atoms, or R.sub.2, R.sub.3 and R.sub.4 can form a part of a heterocyclic ring, with the proviso that the combined total of carbon atoms is between 16 and 40.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: In a method for administering systemically active agents including therapeutic agents through the skin or other body membranes of humans and animals typically in the form of a transdermal device or formulation, the improvement comprising the use therewith of an effective amount of a membrane penetration enhancer having the structural formula. ##STR1## wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17.

Abstract: There is disclosed a method of improvement of dyeing fibers by utilizing in the dyeing process, an effective, dye-enhancing amount of a textile auxiliary having the structural formula ##STR1## wherein R' is H or a lower alkyl group having 1-4 carbon atoms, n is O or a positive integer from 1-11 and R is an alkyl group (straight or branch chain) having 1-18 carbon atoms or aryl group, e.g., phenyl. The compounds disclosed herein enhance dye penetration of fibers and allow the dyeing process to take place at lower temperatures in less time.

Abstract: There is disclosed a method of treatment of inflammation in humans and animals comprising contacting the inflamed area with an effective, anti-inflammatory amount of 1-dodecylazacycloheptan-2-one.

Abstract: The disclosure describes a method for selectively inhibiting thromboxane biosynthesis with Burimamide, a compound previously known to be a histamine H.sub.2 -receptor blocker. The discovery is useful in the treatment of a number of cardiovascular and inflammatory diseases in which thromboxane biosynthesis is involved.

Abstract: A therapeutic composition comprising a topically administrable ophthalmic pharmaceutical carrier and colchicine. The foregoing composition temporarily alleviates the symptoms of glaucoma when topically administered to the eye.

Abstract: A therapeutic composition comprising a topically administrable ophthalmic pharmaceutical carrier and vinblastine. The fore-going composition temporarily alleviates the symptoms of glaucoma when topically administered to the eye.

Abstract: The disclosure describes a method for selectively inhibiting thromboxane biosynthesis with Burimamide, a compound previously known to be a histamine H.sub.2 -receptor blocker. The discovery is useful in the treatment of a number of cardiovascular and inflammatory diseases in which thromboxane biosynthesis is involved.

Abstract: A process for inhibiting platelet aggregation or thrombus formation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, Y is H, alkyl, dialkylaminoethyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R, and R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##STR2## NHCOR.sub.1, NR.sub.1 R.sub.2 or ##STR3## where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl; R, R.sub.1 and R.sub.2 being the same or different, T is selected from the group consisting of O, NH, S and CH.sub.2 with the proviso that only one T is O, Z is 0 or 1 and n is 0-5; and pharmaceutically acceptable salts thereof, to in vivo and in vitro platelet systems.

Abstract: A process for inhibiting platelet aggregation or thrombus formation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, Y is H, alkyl, dialkylaminoethyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R, and R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##STR2## NHCOR.sub.1, NR.sub.1 R.sub.2 or ##STR3## where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl; R, R.sub.1 and R.sub.2 being the same or different and n is 0-5; and pharmaceutically acceptable salts thereof, to in vivo and in vitro platelet systems.

Abstract: There is disclosed a shelf-stable microbicidal composition containing no water and including an ene-diol compound, a specific catalytic metal compound, and a propellant suitable for dispensing the ingredients from an aerosol container, with at least one of the ene-diol compound and the catalytic metal compound not in solution. Oxidation of the ene-diol compound catalyzed by the metal compound produces a microbicidal effect.